Evidence & regulatory context
- Mechanism
- Intracellular LAR peptide (ILP) and intracellular sigma peptide (ISP), TAT-conjugated PTPsigma/LAR-blocking peptides.
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryCompressionSprague-Dawley in vivo; C57BL/6 mice and postnatal P1 to P3 Sprague-Dawley pups used in vitroFemalen = 112 adult female Sprague-Dawley rats in total, plus 6 C57BL…Intrathecal, delivered by Alzet osmotic mini-pump via an indwelling catheter with the tip rostral to the lesion10 micrograms of each peptide per day in vivo; 10 micromola…Infusion began immediately after spinal cord injury
Model: Clip-compression spinal cord injury: T6 to T8 laminectomy followed by extradural application of a 35 g aneurysm clip at T7 for 1 min
ILP and ISP shifted the injury response towards an M2 macrophage and regulatory T cell profile with raised IL-10, Arginase-1 and FOXP3 and reduced myeloperoxidase, IL-1beta and IFN-gamma positive effector T cells, but did not alter overall macrophage recruitment, MMP-2 or MMP-9 activity, or GFAP an…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.